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Background: Panax ginseng (i.e., ginseng) root is extensively used in traditional oriental medicine. It is a
modern pharmaceutical reagent for preventing various human diseases such as cancer. Ginsenosidesdthe
major active components of ginsengdexhibit immunomodulatory effects. However, the mechanism and
function underlying such effects are not fully elucidated, especially in human monocytes and dendritic
cells (DCs).
Methods: We investigated the immunomodulatory effect of ginsenosides from Panax ginseng root on
CD14þ monocytes puriﬁed from human adult peripheral blood mononuclear cells (PBMCs) and on their
differentiation into DCs that affect CD4þ T cell activity.
Results: After treatment with ginsenoside fractions, monocyte levels of tumor necrosis factor (TNF)-a,
interleukin (IL)-6, and IL-10 increased through phosphorylation of extracellular signal-regulated kinase
(ERK)1/2 and c-Jun N-terminal kinase (JNK), but not p38 mitogen-activated protein kinase (MAPK). After
treatment with ginsenoside fractions, TNF-a production and phosphorylation of ERK1/2 and JNK
decreased in lipopolysaccharide (LPS)-sensitized monocytes. We conﬁrmed that DCs derived from CD14þ
monocytes in the presence of ginsenoside fractions (Gin-DCs) contained decreased levels of the cos-
timulatory molecules CD80 and CD86. The expression of these costimulatory molecules decreased in
LPS-treated DCs exposed to ginsenoside fractions, compared to their expression in LPS-treated DCs in the
absence of ginsenoside fractions. Furthermore, LPS-treated Gin-DCs could not induce proliferation and
interferon gamma (IFN-g) production by CD4þ T cells with the coculture of Gin-DCs with CD4þ T cells.
Conclusion: These results suggest that ginsenoside fractions from the ginseng root suppress cytokine
production and maturation of LPS-treated DCs and downregulate CD4þ T cells.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Panax ginseng (i.e., ginseng) is a well-known traditional oriental
medicine used to prevent various human diseases such as inﬂam-
matory diseases and cancer [1,2]. Ginsenosides are a major
component of ginseng and more than 25 ginsenosides reportedlyevelopment, School of Agricultura
rk.
erms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, Publexist [3]. Ginsenosides can activate macrophages to produce reac-
tive nitrogen intermediates and induce a tumoricidal effect [4].
However, they may also attenuate cytokine production [5].
Monocytes comprise approximately 5e10% of blood leukocytes
in humans [6] and mice [7]. They have an important role in
establishing innate immune responses. Monocytes differentiatel Biotechnology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-921,
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
ished by Elsevier. All rights reserved.
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appropriate mediators such as granulocyte macrophage colony-
stimulating factor (GM-CSF), macrophage colony-stimulating factor
(M-CSF), or interleukin 4 (IL-4) [8]. On stimulation with lipopoly-
saccharide (LPS), monocytes and macrophages produce proin-
ﬂammatory cytokines such as tumor necrosis factor (TNF)-a and
the chemokines. Dendritic cells have a major role in initiating and
inducing innate immunity and, perhaps more importantly, bridging
with antigen-speciﬁc immune responses elucidated by T cells.
Compared to monocytes, immature DCs display higher expression
levels of CD80, CD86, CD11c, and major histocompatibility complex
(MHC) class II, and have increased antigen uptake [9]. After antigen
uptake, immature DCs become mature and sensitize naive T cells,
which leads to clonal expansion and differentiation into effector
helper T cells and cytotoxic T cells, which produce IFN-g.
Mouse DCs treatedwith ginsenosides in a recent study showed a
suppressed maturation process [10]. In mouse DCs stimulated with
LPS, the ginsenosides inhibit the secretion of IL-12, an important
cytokine that induces T cell activation. However, no reports have
revealed the effect of ginsenosides on the differentiation of
immature DCs from human monocytes. In the present study, we
therefore explored the effect of ginsenoside fractions on the dif-
ferentiation of CD14þ monocytes to DCs, and explored the
expression of cell surface markers (e.g., CD80, CD86, CD40, and
MHC class II) on the differentiated DCs and interferon gamma
(IFN-g) production in CD4þ T cells when cocultured with DCs that
were differentiated in the presence of ginsenoside fractions.
2. Materials and methods
2.1. Reagents and chemicals
Roswell Park Memorial Institute (RPMI) 1640 medium, fetal
bovine serum (FBS), and antibiotics (e.g., penicillin and streptomycin)
were purchased from Gibco-BRL (Grand Island, NY, USA). Escherichia
coli LPS (026:B6), the c-Jun N-terminal kinase (JNK) inhibitor
SP600125, and polymyxin B (PMB) were purchased from Sigmae
Aldrich (St. Louis, MO, USA). The mitogen-activated protein kinase
(MAPK) inhibitor U0126 was purchased from EMD Millipore (San
Diego, CA, USA). Human recombinant IL-4, GM-CSF, and anti-
Annexin-V-FITC antibody were purchased from R&D Systems (Min-
neapolis, MN, USA). Rabbit antiphospho-extracellular signal-regu-
lated kinase 1/2 (antiphospho-ERK1/2), anti-ERK1/2, antiphospho-
JNK, anti-JNK, antiphospho-p38, anti-p38, and anti-inhibitory kappa
B (anti-IkB) antibodies were purchased from Cell Signaling Technol-
ogy (Danvers, MA, USA). Goat antimouse immunoglobulin G-horse-
radish peroxidase (IgG-HRP), mouse antirabbit IgG-HRP, and mouse
monoclonal anti-b-actin were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). The speciﬁc antibodies for ﬂow cyto-
metric analysis, which included human anti-CD80-PE, anti-CD86-
antigen-presenting cell (APC), anti-CD40-ﬂuorescein isothiocyanate
(FITC), anti-CD14-FITC, anti-CD11c-APC, and anti-human leukocyte
antigen DR (HLA-DR)-FITCwere purchased from BD Biosciences (San
Diego, CA, USA). Unless otherwise noted, all other reagents were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Ginsenoside preparation
Ginsenoside fractions were extracted from Panax ginseng, as
previously described [11]. In brief, the dried root of Panax ginsengwas
reﬂuxed twicewith 80%methanol and concentrated with a vacuum-
evaporator. The concentratewas dilutedwithwater and the solution
was extractedwith1 L of diethyl ether. The aqueousphasewasbrieﬂy
evaporated under vacuum to remove the remaining ether. The so-
lution was then extracted with n-butanol. The organic phase wasﬁnally collected and evaporated. Endotoxin levels in the ginsenoside
preparations were determined using a Limulus amebocyte lysate test
kit (Cambrex Bio Science, Walkersville, MD, USA) in accordancewith
the manufacturer’s instructions. For each experiment, 100 mg of the
ginsenoside fractions were dissolved in 5 mL sterile double-distilled
water and diluted 1:1 with phosphate-buffered saline (PBS, Gibco-
BRL) for a ﬁnal concentration of 10 mg/mL.
2.3. Thin-layer chromatography and high-performance liquid
chromatography analyses
For TLC, 8 mL of ginseng extract solution in butanol was spotted
onto a TLC plate (silica gel 60) with standard samples and developed
to 5.5 cm distance in a chamber containing a mobile phase chloro-
form-methanol-water mixture (65:35:10, v/v/v; lower phase). The
bands on the TLC plates were detected by spraying with 10% sulfuric
acid, followed by heating at 110C for 10 min. High-performance
liquid chromatographywas performed by using the NS 3000i system
(Futecs Co., Ltd, Jinju, Korea), which is equipped with a UV detector
and a gradient pump. A 20-mL samplewas injected into a C18 column
(250 mm  4.6 mm, 5mm), and the eluent was withdrawn at a ﬂow
rate of 1.6 mL/min using a solvent gradient consisting of acetonitrile
(A) andwater (W). The solvent A/solventW ratios were 15:85, 21:79,
58:42, 65:35, 90:10, 90:10, and 15:85 with runtimes of 0e5 min, 5e
25 min, 25e70 min, 70e85 min, 85e87 min, 87e97 min, and 97e
110min, respectively. Each ginsenoside fraction peakwasmonitored
and compared with the peak corresponding to the standards (i.e.,
Rb1, Rc, Rd, Rh2, Rg1, Rg3, and compound K) prepared from steamed
and dried Panex ginseng root (KT&G, Daejeon, Korea).
2.4. Preparation of CD14þ monocytes and differentiation into DCs
The Institutional Review Board (IRB Number 0705/001-002) of
the Seoul National University (Seoul, South Korea) approved all
experiments using human blood. Peripheral blood mononuclear
cells (PBMCs) were prepared by density gradient centrifugation of
blood obtained from healthy donors by using the Ficoll-Paque Plus
centrifuge (Amersham Bioscience, Buckinghamshire, UK). Mono-
nuclear cells in the buffy coat were collected and washed three
times with PBS. The CD14þ monocytes were isolated from the
PBMCs by using an IMag anti-human CD14 antibody kit (BD Bio-
sciences). The CD14þ monocytes were suspended in a complete
medium composed of RPMI-1640 glutamax supplementedwith 10%
FBS and 1% antibiotics/antimycotics. To generate DCs,1106 CD14þ
monocytes were cultured for 3 d or 5 d at 37C under 5% carbon
dioxide in RPMI complete medium containing 500 U/mL IL-4 and
800 U/mL GM-CSF in a 24-well culture plate (Nalgene Nunc Inter-
national, Rochester, NY, USA). The medium was changed every 3 d.
2.5. Enzyme-linked immunosorbent assay
For 24 h, CD14þ monocytes (1  106 cells) were treated with
ginsenoside fractions at a concentration of 0 mg/mL, 1 mg/mL, or 10
mg/mL in the presence or absence of LPS (50 ng/mL). The super-
natants were then harvested. In some experiments, CD14þ mono-
cytes were pretreated for 1 h with U0126, SP600125, or PMB. The
levels of IL-1b, IL-6, IL-10, and TNF-a in the supernatants were
analyzed using enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems) in accordance with the manufacturer’s instructions.
2.6. Western blot analysis
The CD14þ monocytes (1  106 cells) were stimulated with
ginsenoside fractions at a concentration of 0 mg/mL,1 mg/mL, and 10
mg/mL in the presence or absence of LPS (50 ng/mL). The cells were
Fig. 1. Components of crude root ginsenoside. The qualitative analysis of the ginsenoside fractions are by (A) thin-layer chromatography and (B) high-performance liquid
chromatography.
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assay lysis buffer containing 50mM Tris-HCl, pH 8, 150mM sodium
chloride,1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), a protease inhibitor cocktail (Roche, Mannheim,Fig. 2. Apoptosis in CD14þ monocytes in the presence or absence of ginsenoside fractions d
(1  106 cells) were cultured with interleukin-4 (IL-4; 500 U/mL) and granulocyte macro
ginsenoside fractions (1 mg/mL or 10 mg/mL). The expression levels of Annexin V and pro
p < 0.05, compared to the control group. CON, control; PI, Propidium iodide.Germany), 2mM sodium ﬂuoride, 0.1mM sodium orthovanadate,
and 2mM glycerol phosphate. Insoluble material was removed by
centrifugation at 22,000  g for 10 min at 4C. The protein con-
centration was determined using the Bio-Rad Protein Assay Kituring their differentiation into dendritic cells. (A and B) For 5 d, the CD14þ monocytes
phage colony-stimulating factor (GM-CSF; 800 U/mL) in the presence or absence of
pidium iodide were measured by ﬂow cytometry. *Indicates statistical signiﬁcance at
Fig. 3. Cytokine production by lipopolysaccharide (LPS)-sensitized CD14þ monocytes
in the presence or absence of ginsenoside fractions. For 24 h, CD14þ monocytes were
treated with ginsenoside fractions (0 mg/mL, 1 mg/mL, or 10 mg/mL). The production of
(A) TNF-a, IL-6, IL-1b, and (B) IL-10 was measured by an enzyme-linked immunosor-
bent assay kit. (C) For 1 h, the cells were pretreated with PMB (50 mg/mL). This was
followed by treatment with ginsenoside fractions (10 mg/mL) and/or lipopolysaccha-
ride (LPS; 50 ng/mL) for an additional 24 h. The culture supernatants were collected
and the TNF-a levels were measured. Statistical signiﬁcance is denoted by *p < 0.05,
**p < 0.01, and ***p < 0.001, compared to the control group. GF, ginsenoside fraction;
IL, interleukin; PMB, polymyxin B; TNF-a, tumor necrosis factor alpha.
J Ginseng Res 2015;39:29e3732(Bio-Rad Laboratories, Hercules, CA, USA). The lysates were sepa-
rated by SDS-polyacrylamide gel electrophoresis (PAGE) and
transferred to a polyvinylidene diﬂuoride microporous membrane
(Amersham Biosciences, Piscataway, NJ, USA). The membranes
were blocked at room temperature for 1 h with 3% bovine serum
albumin (BSA) in tris-buffered saline (TBS) containing 0.1% Tween
20 prior to probing with a primary antibody for the non-
phosphorylated or phosphorylated forms of MAPKs or mouse anti-
b-actin. Primary antibodies were detected using goat antimouse
IgG-HRP or mouse antirabbit IgG-HRP antibodies. They were
visualized with an enhanced chemiluminescence system (GE
Healthcare, Buckinghamshire, UK), after the membrane had been
extensively washed with TBS containing 0.1% Tween 20. For the
MAPK signaling inhibition test, the cells were pretreated for 1 h
with 20mM SP600125 (i.e., JNK inhibitor) and 10mM U0126 (i.e.,
MAPK inhibitor) prior to being treated with ginsenoside fractions.
2.7. Flow cytometric analysis
The CD14þ monocytes were seeded into a 24-well plate at a
density of 1106 cells/mL in RPMI completemedia containing GM-
CSF and IL-4. The cells were then treated with ginsenoside fractions
for 3 d or 5 d. In an additional experiment, immature DCs were
stimulated with LPS (50 ng/mL) in the presence or absence of the
ginsenoside fractions. The cells were then harvested and stained
with an appropriate combination of antihuman-CD80-PE, anti-
CD86-APC, anti-CD40-FITC, anti-CD14-FITC, anti-CD11c-APC, and
anti-HLA-DR-FITC antibodies. After staining for 25 min at 4C, the
cells were washed three times, and differences in the expression
of cell surface molecules were analyzed by a ﬂow cytometer
(BD FACScalibur; BD Biosciences) with CellQuest software
(BD Biosciences). All ﬂow cytometric data were analyzed by FlowJo
software (Tree Star, San Carlos, CA, USA).
2.8. Apoptosis assay
The CD14þ monocytes were seeded onto a 24-well plate at a
density of 1106 cells/mL in RPMI completemedia containing GM-
CSF and IL-4. The cells were treated with ginsenoside fractions for 5
d and then harvested and stained with anti-Annexin V antibody
and propidium iodide (PI). After staining for 15 min at 4C under
dark conditions, the cells were washed with cold PBS. Cell death
was assessed by using a ﬂow cytometer (BD Biosciences) and
FlowJo software (Tree Star).
2.9. Measurement of T cell activity
The CD4þ T cells were isolated and activated, as previously
described [12]. In brief, after differentiating DCs with or without
ginsenoside fraction treatment, the cells were stimulated for 2
d with ethanol-killed Staphylococcus aureus (107 colony-forming
units (CFU)/mL) [12]. After washing with PBS, 2  105 cells were
cocultured in a 96-well plate with CD4þ T cells (2  105 cells)
labeled with carboxyﬂuorescein succinimidyl ester (CFSE) (Invi-
trogen, Carlsbad, NM, USA). After 5 d, the cells were harvested and
washed with PBS. The intensity of CFSE was determined by ﬂow
cytometry. After culturing for 3 d, the IFN-g levels in the super-
natants were determined using an ELISA kit (R&D Systems).
2.10. Statistical analysis
Comparative data were analyzed by the Student t test using the
SAS statistical software package, version 9.3 (SAS Institute Inc.,
Cary, NC, USA). Differences were considered statistically signiﬁcant
when p < 0.05.3. Results
3.1. Characterization of ginsenoside fractions
We initially examined the proportion of each ginsenoside fraction
in the sample by using TLC, which is a common technique for the
ﬁngerprint analysis of amixed complex because of its ease of use, low
cost, and versatility. As Fig. 1A shows, Rg3, Rd, and Rb1 were the
predominant components. We then examined the ginsenoside frac-
tion further by using high performance liquid chromatography. As
expected from TLC results, Rb1, Rg3, and Rd were the major compo-
nents in the ginseng root, and the largest fraction was Rc (Fig. 1B).
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ginsenoside fractions
First, to examine the cytotoxicity of the ginsenoside fractions on
CD14þ monocytes, we analyzed apoptosis of CD14þ monocytes by
using Annexin V/PI for the ﬁrst 5 d of differentiation. The ginse-
noside fractions did not show anymajor signs of inducing apoptosis
(Fig. 2A and B). These results suggested that 1 mg/mL or 10 mg/mL of
ginsenoside fractions was a valid concentration to use for further
experiments during DC differentiation.
Second, to determine the effect of ginsenoside fractions on
cytokine responsesof CD14þmonocytes, the cellswere treated for24
h with ginsenoside fractions at a concentration of 0 mg/mL, 1 mg/mL,
or 10mg/mL. The supernatantwasexamined for cytokineproduction.Fig. 4. Activation of ERK1/2 and JNK signaling in lipopolysaccharide (LPS)-sensitized CD14
stimulated with LPS (50 ng/mL) for 30 min or with ginsenoside fractions (10 mg/mL) for 0 min
each cell lysate were subjected to Western blot analysis for changes in pERK and pJNK act
treatment with (B and D) 10 mM U0126 or (C and E) 20 mM SP600125, the cells were treated w
mL). (B and C) The production of TNF-a was measured by enzyme-linked immunosorbent a
ERK1/2, extracellular signal-regulated kinase 1/2; GF, ginsenoside fraction; IL-10, interleuki
factor alpha.As Fig. 3A shows, the expression of TNF-a (p < 0.001) and IL-6
(p < 0.01) increased signiﬁcantly after treatment with ginsenoside
fractions (at the concentration of 10 mg/mL), but IL-1b showed
minimal changes. As Fig. 3B shows, IL-10 interestingly also increased
in a dose-dependent manner. To conﬁrm whether the induction of
cytokineswas because the ginsenoside fractionswere contaminated
with LPS, an LPS neutralization assay was performed, after the
addition of PMB, which inhibits the LPS response [13]. As expected,
the production of TNF-a in LPS-treated cells decreased signiﬁcantly
(p ¼ 0.00082) after PMB treatment, whereas no change occurred
with PMB treatment in the cells stimulated with the ginsenoside
fractions (Fig. 3C). This suggests that therewasno LPS contamination
in the ginsenosides. When cotreated with LPS and ginsenosides,
TNF-a induction decreased signiﬁcantly (p¼ 0.00005), compared toþ monocytes with or without ginsenoside fractions. (A) The CD14þ monocytes were
, 5 min, 15 min, 30 min, 60 min, 120 min, or 360 min. Forty micrograms of protein from
ivity. The results are representative of three independent experiments. After 1 h pre-
ith ginsenoside fractions (10 mg/mL) for 24 h in the presence or absence of LPS (50 ng/
ssay. (D and E) The phosphorylation of ERK1/2 and JNK was evaluated by Western blot.
n 10; JNK, c-Jun N-terminal kinase; pERK, phosphorylated ERK; TNF-a, tumor necrosis
J Ginseng Res 2015;39:29e3734the cells treated with LPS alone. These results indicate that ginse-
noside fractions induce cytokine production in CD14þ monocytes
and suppress LPS-induced immune responses.
3.3. The ability of ginsenoside fractions to enhance cytokine
production is mediated through ERK1/2 and JNK signaling
Most studies on ginseng have focused on a single ginsenoside
compound. However, the mechanisms by which total ginsenosides
modulate the activity of human monocytes have not yet been re-
ported. Thus, we examined the changes in MAPK (ERK1/2, JNK, and
p38) and nuclear factor kappa B (NF-kB) signaling in CD14þ
monocytes treated with ginsenoside fractions. The phosphoryla-
tion of ERK1/2 and JNK increased in cells treated with ginsenoside
fractions in a time-dependent manner (Fig. 4A), whereas the
phosphorylation of p38 and IkB did not change (data not shown). To
conﬁrm these results, cytokine production was measured after
blocking the activities of ERK1/2 and JNK. The production of TNF-a
in cells treated with ginsenoside fractions decreased signiﬁcantly
(Fig. 4B and C) after the addition of ERK1/2 or JNK inhibitors (Fig. 4DFig. 5. Suppression of the expression of cell surface molecules during dendritic cell differen
treated with interleukin 4 (IL-4; 500 U/mL) and granulocyte macrophage colony-stimulatin
area, 0 mg/mL; dotted line, 1 mg/mL; unbroken line, 10 mg/mL) for (A) 3 d or (B) 5 d. The exp
were measured by ﬂow cytometry. The numbers in the panels indicate the mean ﬂuorescenc
mg/mL, respectively. The data are representative of three independent experiments. MHC, mand E). These data suggest that ginsenosides induce cytokine
secretion via the activation of phosphorylated ERK1/2 (pERK1/2)
and phosphorylated JNK (pJNK) signaling in CD14þ monocytes.
3.4. Ginsenosides attenuate the differentiation of CD14þ monocytes
into DCs
Monocytes differentiate into DCs when cultured in the presence
of GM-CSF and IL-4 [8]. To test whether ginsenoside fraction is
involved in DC differentiation, CD14þ monocytes were incubated
with GM-CSF and IL-4 in the presence or absence of ginsenoside
fractions for 3 d or 5 d, and the expression of cell surface and
maturationmarkers (i.e., CD80, CD86, CD40, CD11c, CD14, andMHC
class II) was measured [9]. Three days after the treatment, little to
no change had occurred (Fig. 5A). However, 5 d after the treatment,
the ginsenoside fractions suppressed the expression of CD80, CD86,
CD40, and CD11c, but not MHC class II and CD14 (Fig. 5B). These
results indicate that DCs treated with ginsenoside fractions during
the maturation process express low levels of costimulatory
molecules.tiation in the presence or absence of ginsenoside fractions. The CD14þ monocytes were
g factor (GM-CSF; 800 U/mL) in the presence or absence of ginsenoside fractions (gray
ression levels of the surface markers CD80, CD86, CD40, MHC class II, CD11c, and CD14
e intensity of each ginsenoside molecule at the concentration of 0 mg/mL, 1 mg/mL, or 10
ajor histocompatibility complex.
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exhibit impaired maturation status and T cell activation
Mature DCs express higher levels of surface markers such as
CD80, CD86, CD40, and CD83, compared to immature DCs [14].
Therefore, to further examine the characteristics of DCs differenti-
ated in the presence of ginsenoside fractions (Gin-DCs), the Gin-
DCs were treated with LPS. To identify the impact of Gin-DCs on the
maturation process, we measured the expression of the surface
markers CD80, CD86, CD40, and MHC class II. As Fig. 6A shows, the
expression of these markers decreased in a dose-dependent
manner, whereas the expression of CD40 remained relatively
unchanged.
To investigate whether Gin-DCs activate CD4þ T cells, the Gin-
DCs were primed for 2 d with ethanol-killed S. aureus [12]. They
were then cocultured with CFSE-labeled CD4þ T cells for an addi-
tional 3 d or 5 d. The CD4þ T cell proliferation was slightly sup-
pressed when cocultured with S. aureus-primed Gin-DCs for 5 days
(Fig. 6B). In addition, IFN-g production decreased signiﬁcantly
(p < 0.05) under the same conditions (Fig. 6C). These results sug-
gest that ginsenoside fractions reduce the capacity of DCs to acti-
vate CD4þ T cells, compared to control DCs.Fig. 6. Dendritic cell (DC) maturation in the presence of ginsenoside fractions and the regu
dotted, and broken lines indicate 0 mg/mL, 1 mg/mL, and 10 mg/mL, respectively) during diffe
CD80, CD86, CD40, and MHC class II was assessed by ﬂow cytometry. The gray area indica
ﬂuorescence intensity (MFI) of the gray area, unbroken line, dotted line, and broken line. (B)
primed to DCs treated with ginsenoside fractions (the gray area, unbroken line, and dotted
with CFSE-labeled CD4þ T cells for 3 d or 5 d. Proliferation was then evaluated by ﬂow cytom
d culture were measured by enzyme-linked immunosorbent assay. Statistical signiﬁcance is
major histocompatibility complex.4. Discussion
The major ﬁndings of the current study were the following: (1)
ginsenoside fractions increased the production of IL-6, IL-10, and
TNF-a by human CD14þ monocytes; (2) treatment with ginseno-
side fractions increased the production of TNF-a through ERK1/2
and JNK signaling pathways, but they inhibited LPS-induced cyto-
kine production; (3) ginsenoside fractions suppressed the expres-
sion of cell surface molecules during the differentiation of
monocytes to DCs; and (4) Gin-DCs exhibited low expression of
costimulatory molecules, thereby inhibiting their capacity to acti-
vate CD4þ T cells.
The levels IL-6, TNF-a, and IL-10, but not IL-1b, signiﬁcantly
increased in human monocytes after ginsenoside fraction treat-
ment, which suggests that ginsenosides could modulate the action
mode of monocytes. The expression of IL-10 increased in mono-
cytes treated with ginsenosides, which interestingly indicated
possible anti-inﬂammatory activity under inﬂammatory condi-
tions. Ginsenoside showed no effect on IL-1b production. In LPS-
stimulated human monocytes, TNF-a and IL-1b are differentially
regulated [15]. Therefore, it is reasonable to assume that the various
ginsenoside components exert different effects on cytokinelation of CD4þ T cells. (A) The DCs treated with ginsenoside fractions (the unbroken,
rentiation were stimulated with lipopolysaccharide (LPS) for 24 h. Their expression of
tes the untreated DCs (i.e., the control). The numbers in the panels indicate the mean
During differentiation for 48 h, ethanol-killed Staphylococcus aureus (107 CFU/mL) was
line indicate 0 mg/mL, 1 mg/mL, and 10 mg/mL, respectively). The cells were cocultured
etry. (C) The interferon gamma (IFN-g) levels in the supernatants at the end of the 3-
denoted at *p < 0.05 and **p < 0.01. CFSE, carboxyﬂuorescein succinimidyl ester; MHC,
J Ginseng Res 2015;39:29e3736induction. These results led us to investigate the mechanism by
which ginsenoside fractions induce cytokine production in
monocytes.
The Rg1 ginsenoside activates ERK1/2 in MCF-7 human breast
cancer cells [16], and compound K activates JNK and p38 phos-
phorylation in HT-29 human colon cancer cells [17].
The anticancer and immune-regulative effects of ginseng are
controversial. The ginsenoside Rg1 suppresses the expression of
TNF-a, whereas Rh1 increases TNF-a expression in THP-1 human
leukemia cells [18]. In addition, the ginsenoside Rh1 inhibits the
activation of MAPK signaling in THP-1 cells [19]. The ginsenosides
Rg and Rh2 inhibit the production of proinﬂammatory cytokines
via suppressing activator protein 1 and protein kinase A activity,
but they have no effect on NF-kB activity [20]. Our results suggest
that the ERK1/2 and JNK pathways, but not the p38 MAPK
pathway, are responsible for the ginsenoside-mediated expression
of TNF-a.
Ginsenoside fraction-treated LPS-sensitized monocytes
showed ERK1/2 and JNK phosphorylation that was superior to
that of the cells stimulated with LPS alone. These results indicate
that the ginsenosides are forceful activators of these signaling
pathways. Our results further suggested that ginsenoside frac-
tions modulate LPS-induced inﬂammatory effects in human
monocytes.
Because of the wide variability in the type and concentration of
ginsenosides in ginseng extracts, the deﬁnition of the immuno-
modulatory potential of each ginsenoside component is crucial.
The ginsenoside Rg1 indeed inhibited the production of TNF-a and
IL-6, whereas Rb1 affected IL-6 production only. The combination
of Rg1 and Rb1 unexpectedly diminished such inhibitory effects.
These ﬁndings are consistent with our results and with reports
from other studies that suggest that ginseng extracts differentially
affect immune cell function, based on their speciﬁc ginsenoside
proﬁle [21].
Our results are in agreement with those of previous reports
showing that DCs expressing low levels of costimulatory molecules
weakly induce T cell proliferation and T cell secretion of IFN-g
[22,23]. Furthermore, LPS-stimulated Gin-DCs expressed low levels
of costimulatory molecules. When cocultured with CD4þ T cells,
ethanol-killed S. aureuseprimed Gin-DCs induced decreased CD4þ
T cell proliferation and IFN-g production, compared to the control
DCs [12].
Several studies have recently suggested that tolerogenic DCs
that express low levels of costimulatorymolecules and produce low
levels of proinﬂammatory cytokines also suppress T cell prolifera-
tion and cytokine production [24e26]. The Gin-DCs share some
characteristics with tolerogenic DCs such as the low expression
levels of costimulatory molecules; however, Gin-DCs continuously
produce proinﬂammatory cytokines (data not shown). As
mentioned previously, ginsenosides consist of a number of com-
pounds such as Re, Rh, and Rg. Different combinations of these
compounds may cause different responses in DCs. These features of
the ginsenosides (not a single compound) may therefore be
responsible for the low expression levels of costimulatory mole-
cules by DCs. Because of the immunomodulatory activities reported
in this paper, the precise mechanism by which ginsenosides regu-
late the expression of costimulatory molecules by DCs should be
investigated further.
In conclusion, ginsenoside fractions promote the production of
inﬂammatory cytokines in CD14þ monocytes via ERK1/2 and JNK
signaling pathways. However, DCs differentiated from monocytes
do not fully activate CD4þ T cells in the presence of ginsenoside
fractions. This is likely because they express low levels of cos-
timulatory molecules. These results suggest that ginsenosides may
alleviate inﬂammatory symptoms.Conﬂicts of interest
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